To include your compound in the COVID-19 Resource Center, submit it here.

rVWF: Phase I data

A single-blind, dose-escalating, crossover Phase I trial in 32 patients with type 3

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE